Thomas Jefferson University

Robert Capizzi

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-5699
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    P30CA012197     (MESA, RUBEN A.)Mar 1, 1976 - Jan 31, 2027
    NIH
    Cancer Center Support Grant
    Role: Co-Principal Investigator
    U10CA033499     (CAPIZZI, ROBERT L)Jul 1, 1982 - Jun 30, 1987
    NIH
    REGIONAL COLLABORATIVE PROGRAM - POA BGSM
    Role: Principal Investigator
    R01CA036000     (CAPIZZI, ROBERT L)Feb 1, 1983 - Jul 31, 1987
    NIH
    PHARMACOLOGICAL DETERMINANTS AFFECTING CLINICAL TRIALS
    Role: Principal Investigator
    U10CA037378     (COOPER, M ROBERT)Sep 15, 1983 - May 31, 1997
    NIH
    CCCWFU RESEARCH BASE-COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Yin W, Loadman P, Capizzi R, Grieshaber C, Fumoleau P. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. Eur J Cancer. 2010 Mar; 46(4):729-34. PMID: 20031390.
      Citations:    
    2. Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk Res. 2010 Apr; 34(4):487-91. PMID: 19748672.
      Citations:    
    3. Chau M, Christensen JL, Ajami AM, Capizzi RL. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res. 2008 Mar; 32(3):465-73. PMID: 17826829.
      Citations:    
    4. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005 Jun 15; 105(12):4576-82. PMID: 15731177.
      Citations:    
    5. Grosso D, Filicko J, Garcia-Manero G, Beardell F, Brunner J, Cohn J, Ferb?r A, Martinez J, Mookerjee B, Rose L, Tice D, Wagner JL, Capizzi R, Flomenberg N. Cytoprotection in acute myelogenous leukemia (AML) therapy. Semin Oncol. 2004 Dec; 31(6 Suppl 18):67-73. PMID: 15726527.
      Citations:    
    6. Capizzi RL. Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas. Trans Am Clin Climatol Assoc. 2004; 115:255-72. PMID: 17060972.
      Citations:    
    7. Jeong YY, Mitchell DG, Hann HW, Malin AK, Kang HK, Holland GA, Capizzi RL. Hepatocellular carcinoma after systemic chemotherapy: gadolinium-enhanced mr measurement of necrosis by volume histogram. J Comput Assist Tomogr. 2001 Jul-Aug; 25(4):624-8. PMID: 11473196.
      Citations:    
    8. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol. 2000 Dec; 72(4):425-35. PMID: 11197208.
      Citations:    
    9. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol. 1999 Apr; 26(2 Suppl 7):72-81. PMID: 10348264.
      Citations:    
    10. Capizzi RL. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent. Semin Oncol. 1999 Apr; 26(2 Suppl 7):1-2. PMID: 10348254.
      Citations:    
    11. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999 Apr; 26(2 Suppl 7):3-21. PMID: 10348255.
      Citations:    
    12. Capizzi RL. Clinical status and optimal use of amifostine. Oncology (Williston Park). 1999 Jan; 13(1):47-59; discussion 63, 67. PMID: 10027198.
      Citations:    
    13. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 1997 Nov 01; 90(9):3364-9. PMID: 9345018.
      Citations:    
    14. Budd GT, Ganapathi R, Adelstein DJ, Pelley R, Olencki T, Petrus J, McLain D, Zhang J, Capizzi R, Bukowski RM. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer. 1997 Sep 15; 80(6):1134-40. PMID: 9305715.
      Citations:    
    15. Taylor CW, Wang LM, List AF, Fernandes D, Paine-Murrieta GD, Johnson CS, Capizzi RL. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer. 1997 Sep; 33(10):1693-8. PMID: 9389935.
      Citations:    
    16. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol. 1996 Aug; 23(4 Suppl 8):58-63. PMID: 8783669.
      Citations:    
    17. Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, Capizzi R, Schein PS, Shpall EJ. Use of amifostine in bone marrow purging. Semin Oncol. 1996 Aug; 23(4 Suppl 8):44-8. PMID: 8783666.
      Citations:    
    18. Paine GD, Taylor CW, Lopez MH, Johnson CS, Capizzi RL. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol. 1996 Aug; 23(4 Suppl 8):35-9. PMID: 8783664.
      Citations:    
    19. Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 1996 Aug; 23(4 Suppl 8):2-17. PMID: 8783661.
      Citations:    
    20. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer. 1996; 32A Suppl 4:S5-16. PMID: 8976816.
      Citations:    
    21. Capizzi RL. Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs. 1996; 14(3):249-56. PMID: 8958179.
      Citations:    
    22. Alberts DS, Speicher LA, Krutzsch M, Wymer J, Capizzi RL, Conlon J, Barrett A, Aickin M. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Eur J Cancer. 1996; 32A Suppl 4:S17-20. PMID: 8976817.
      Citations:    
    23. Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RL, Gorin NC. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood. 1995 Oct 01; 86(7):2849-55. PMID: 7670119.
      Citations:    
    24. Capizzi RL, Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer. 1995; 31A Suppl 1:S8-13. PMID: 7577096.
      Citations:    
    25. Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, Peterson BA, Weiss RB, Omura GA, et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol. 1995; 36(5):425-30. PMID: 7634384.
      Citations:    
    26. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol. 1994 Oct; 21(5 Suppl 11):8-15. PMID: 7973776.
      Citations:    
    27. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer. 1993 Dec 01; 72(11 Suppl):3495-501. PMID: 8242582.
      Citations:    
    28. Chandrasekaran B, Kute TE, Capizzi RL. Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil. Cancer Chemother Pharmacol. 1992; 29(6):455-60. PMID: 1568288.
      Citations:    
    29. Powell BL, White JC, Gregory BW, Brockschmidt JK, Rhinehardt-Clark A, Lyerly ES, Chorley HM, Capizzi RL. S-phase fraction is not correlated with nucleoside transport in acute myeloid leukemia cells. Leukemia. 1991 Jul; 5(7):598-601. PMID: 2072744.
      Citations:    
    30. Powell BL, Kute TE, Craig JB, Lyerly ES, Gregory BW, Do KA, Contento MM, Capizzi RL. Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase. Leukemia. 1990 May; 4(5):316-20. PMID: 2388477.
      Citations:    
    31. Muss HB, Spell N, Scudiery D, Capizzi RL, Cooper MR, Cruz J, Jackson DV, Richards F, Spurr CL, White DR, et al. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs. 1990 Feb; 8(1):125-30. PMID: 2345067.
      Citations:    
    32. Capizzi RL. More on the treatment of relapsed acute myeloid leukemia. Oncology (Williston Park). 1989 Oct; 3(10):72-4. PMID: 2701211.
      Citations:    
    33. Smith WJ, Muss HB, Capizzi RL, White DR, Richards F, Jackson DV, Powell BL, Zekan PJ. Mitoxantrone and high-dose ara-C in refractory malignancies: a phase I trial. Med Pediatr Oncol. 1989; 17(2):159-63. PMID: 2704336.
      Citations:    
    34. Powell BL, Capizzi RL, Muss HB, Bearden JD, Lyerly ES, Rosenbaum DL, Morgan TM, Richards F, Jackson DV, White DR, et al. Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia. 1989 Jan; 3(1):23-8. PMID: 2642574.
      Citations:    
    35. Powell BL, Craig JB, Muss HB, Zekan PJ, Cooper MR, Schnell FM, Hampton JW, White DR, Smith LR, Capizzi RL. Phase II trial of high-dose cytosine arabinoside and cisplatin in recurrent squamous carcinoma of the head and neck. A Piedmont Oncology Association Study. Am J Clin Oncol. 1988 Oct; 11(5):550-2. PMID: 3177257.
      Citations:    
    36. Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Powell BL, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1988 Jul; 6(7):1098-106. PMID: 3292710.
      Citations:    
    37. Powell BL, Craig JB, Capizzi RL, Richards F. Phase I-II trial of acivicin in adult acute leukemia. Invest New Drugs. 1988 Apr; 6(1):41-4. PMID: 3165971.
      Citations:    
    38. Powell BL, Capizzi RL, Jackson DV, Richards F, Muss HB, Lyerly ES, Rosenbaum DL, Connelly RA, Buss DH, Bearden JD, et al. Low dose Ara-C for patients with myelodysplastic syndromes. Leukemia. 1988 Mar; 2(3):153-6. PMID: 3347093.
      Citations:    
    39. Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper MR, Dillman R, Major WB, Dupre E, McIntyre OR. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study. J Clin Oncol. 1988 Mar; 6(3):499-508. PMID: 3162515.
      Citations:    
    40. Capizzi RL, White C. The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia. Yale J Biol Med. 1988 Jan-Feb; 61(1):11-22. PMID: 3163212.
      Citations:    
    41. Capizzi RL, Powell BL. Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias. Semin Oncol. 1987 Jun; 14(2 Suppl 1):40-50. PMID: 3589697.
      Citations:    
    42. Powell BL, Zekan PJ, Muss HB, Richards F, Lyerly ES, Capizzi RL. Ara-C syndrome during low-dose continuous infusion therapy. Med Pediatr Oncol. 1986; 14(6):310-2. PMID: 3784982.
      Citations:    
    43. Capizzi RL, Powell BL, Cooper MR, Rathmell JP, White JC, Muss HB, Richards F, Jackson DV, Stuart JJ, White DR, et al. Dose-related pharmacologic effects of high dose ara-C and its use in combination with asparaginase for the treatment of patients with acute non-lymphocytic leukemia. Scand J Haematol Suppl. 1986; 44:17-39. PMID: 3457437.
      Citations:    
    44. Powell BL, Capizzi RL, Lyerly ES, Cooper MR. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia. J Clin Oncol. 1986 Jan; 4(1):95-7. PMID: 3001234.
      Citations:    
    45. Atkins JN, Muss HB, Capizzi RL, Cooper MR, Craig J, Cruz JM, Jackson DV, Powell B, Richards F, Spurr CL, et al. Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):897-9. PMID: 4040427.
      Citations:    
    46. Capizzi RL, Powell BL, Cooper MR, Stuart JJ, Muss HB, Richards F, Jackson DV, White DR, Spurr CL, Zekan PJ, et al. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia. Semin Oncol. 1985 Jun; 12(2 Suppl 3):105-13. PMID: 3892697.
      Citations:    
    47. Muss HB, Capizzi RL, Atkins JN, Powell BL, Cooper MR, Ferree D, McMahan RA, Jobson V, Craig J, Homesley HD, et al. Phase I trials of high-dose cytosine arabinoside (HDara-C) and HDara-C plus cisplatin in patients with advanced malignancies. Semin Oncol. 1985 Jun; 12(2 Suppl 3):166-70. PMID: 4040264.
      Citations:    
    48. Capizzi RL, Yang JL, Rathmell JP, White JC, Cheng E, Cheng YC, Kute T. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. Semin Oncol. 1985 Jun; 12(2 Suppl 3):65-74. PMID: 3892704.
      Citations:    
    49. Ross DW, Capizzi RL. Differentiation versus cytoreduction during remission induction in acute nonlymphoblastic leukemia treated with sequential high-dose ara-C and asparaginase. Cancer. 1984 Apr 15; 53(8):1651-4. PMID: 6697302.
      Citations:    
    50. Capizzi RL, Poole M, Cooper MR, Richards F, Stuart JJ, Jackson DV, White DR, Spurr CL, Hopkins JO, Muss HB, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood. 1984 Mar; 63(3):694-700. PMID: 6696996.
      Citations:    
    51. Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng YC. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol. 1983 Dec; 1(12):763-71. PMID: 6668493.
      Citations:    
    52. Capizzi RL, Cheng YC. Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia. Med Pediatr Oncol. 1982; 10 Suppl 1:221-8. PMID: 6962320.
      Citations:    
    53. Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer. 1979 Oct; 44(4):1189-93. PMID: 498009.
      Citations:    
    54. Capizzi RL, Keiser LW, Sartorelli AC. Combination chemotherapy--theory and practice. Semin Oncol. 1977 Jun; 4(2):227-53. PMID: 327555.
      Citations:    
    55. Capizzi RL. The place of pharmacology in cancer medicine. Semin Oncol. 1977 Jun; 4(2):131-3. PMID: 877598.
      Citations:    
    Capizzi's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (199)
    Explore
    _
    Co-Authors (6)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _